These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26643932)

  • 21. Immunity to pertussis 5 years after booster immunization during adolescence.
    Edelman K; He Q; Mäkinen J; Sahlberg A; Haanperä M; Schuerman L; Wolter J; Mertsola J
    Clin Infect Dis; 2007 May; 44(10):1271-7. PubMed ID: 17443462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents--A single blind randomized trial.
    Pavia-Ruz N; Abarca K; Lepetic A; Cervantes-Apolinar MY; Hardt K; Jayadeva G; Kuriyakose S; Han HH; de la O M
    Hum Vaccin Immunother; 2015; 11(7):1770-4. PubMed ID: 26075317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
    Aase A; Herstad TK; Jørgensen SB; Leegaard TM; Berbers G; Steinbakk M; Aaberge I
    Vaccine; 2014 Oct; 32(45):5931-6. PubMed ID: 25218299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
    Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
    Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
    Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
    Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
    McAlister SM; van den Biggelaar AHJ; Woodman TL; Hutton H; Thornton RB; Richmond PC
    Vaccine; 2021 Mar; 39(11):1642-1651. PubMed ID: 33589299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
    Plosker GL
    BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.
    Schure RM; Hendrikx LH; de Rond LG; Oztürk K; Sanders EA; Berbers GA; Buisman AM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1388-95. PubMed ID: 23825195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
    van der Lee S; van Rooijen DM; de Zeeuw-Brouwer ML; Bogaard MJM; van Gageldonk PGM; Marinovic AB; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():681. PubMed ID: 29670634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life.
    Guiso N; Njamkepo E; Vié le Sage F; Zepp F; Meyer CU; Abitbol V; Clyti N; Chevallier S
    Vaccine; 2007 Feb; 25(8):1390-7. PubMed ID: 17134795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
    Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
    Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
    He Q; Tran Minh NN; Edelman K; Viljanen MK; Arvilommi H; Mertsola J
    Infect Immun; 1998 Aug; 66(8):3796-801. PubMed ID: 9673264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.
    Ausiello CM; Urbani F; la Sala A; Lande R; Cassone A
    Infect Immun; 1997 Jun; 65(6):2168-74. PubMed ID: 9169747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
    Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
    Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.
    Tran Minh NN; Edelman K; He Q; Viljanen MK; Arvilommi H; Mertsola J
    Vaccine; 1998 Oct; 16(17):1604-10. PubMed ID: 9713935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.